Q2 FY2026 · ended Jun 30, 2026 · Revenue $101.93M, +156.5% YoY · Filed Aug 13, 2026
Cormedix Inc. (CRMD) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $101.9 million and net income of $26.0 million. Free cash flow was $85.7 million.
Revenue
$101.93M
+156.5% vs year-ago quarter
Net income
$25.99M
+31.1% vs year-ago quarter
Operating cash flow
$86.24M
+187.5% vs year-ago quarter
Free cash flow
$85.68M
+185.9% vs year-ago quarter
EPS
$0.29
+3.6% vs year-ago quarter
Dividend per share
None
Shares outstanding
77.94M
+4.4% vs year-ago quarter
Net cash
$144.24M
Q4 FY2025
Operating margin
47.0%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CRMD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Parsippany, NJ
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1410098
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $101.9M | $127.4M | $128.6M | $101.5M | $39.7M |
| Operating income | $42.9M | $63.7M | $59.1M | $51.3M | $19.5M |
| Net income | $26.0M | $38.6M | $14.0M | $108.6M | $19.8M |
| Diluted EPS | $0.29 | $0.43 | -$0.06 | $1.26 | $0.28 |
| Operating cash flow | $86.2M | $42.4M | $94.5M | $30.9M | $30.0M |
| Free cash flow | $85.7M | $41.7M | $92.7M | $30.4M | $30.0M |
| Total assets | $904.1M | $815.6M | $826.1M | $750.9M | $252.6M |
| Total liabilities | $443.2M | $378.6M | $420.8M | $376.7M | $32.0M |
| Stockholders' equity | $460.8M | $437.0M | $405.3M | $374.1M | $220.6M |
| Cash and investments | $256.7M | $178.1M | $148.5M | $56.6M | $190.7M |
| Total debt | — | — | $4.3M | $4.4M | $435,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 2, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 19, 2026 | Oct 19, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Other events
|
Aug 7, 2026 | Aug 7, 2026 |
| 8-K |
Current report
Other events
|
Jul 2, 2026 | Jun 29, 2026 |
All 1003 Cormedix Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.